Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Delays in Coccidioidomycosis Diagnosis and Associated Healthcare Utilization, Tucson, Arizona, USA.

Donovan FM, Wightman P, Zong Y, Gabe L, Majeed A, Ynosencio T, Bedrick EJ, Galgiani JN.

Emerg Infect Dis. 2019 Sep;25(9):1745-1747. doi: 10.3201/eid2509.190023.

2.

Delays in Coccidioidomycosis Diagnosis and Relationship to Healthcare Utilization, Phoenix, Arizona, USA1.

Ginn R, Mohty R, Bollmann K, Goodsell J, Mendez G, Bradley B, Galgiani JN.

Emerg Infect Dis. 2019 Aug;25(9):1742-1744. doi: 10.3201/eid2509.190019. Epub 2019 Sep 17.

3.

Coccidioidal Meningitis in New York Traced to Texas by Fungal Genomic Analysis.

Barker BM, Rajan S, De Melo Teixeira M, Sewnarine M, Roe C, Engelthaler DM, Galgiani JN.

Clin Infect Dis. 2019 Aug 30;69(6):1060-1062. doi: 10.1093/cid/ciz052.

PMID:
30715178
4.

Glucan-Chitin Particles Enhance Th17 Response and Improve Protective Efficacy of a Multivalent Antigen (rCpa1) against Pulmonary Coccidioides posadasii Infection.

Hung CY, Zhang H, Castro-Lopez N, Ostroff GR, Khoshlenar P, Abraham A, Cole GT, Negron A, Forsthuber T, Peng T, Galgiani JN, Ampel NM, Yu JJ.

Infect Immun. 2018 Oct 25;86(11). pii: e00070-18. doi: 10.1128/IAI.00070-18. Print 2018 Nov.

5.

Characterizing in vitro spherule morphogenesis of multiple strains of both species of Coccidioides.

Mead HL, Teixeira MM, Galgiani JN, Barker BM.

Med Mycol. 2019 Jun 1;57(4):478-488. doi: 10.1093/mmy/myy049.

PMID:
30053114
6.

Viable spores of Coccidioides posadasii Δcps1 are required for vaccination and provide long lasting immunity.

Shubitz LF, Powell DA, Trinh HT, Lewis ML, Orbach MJ, Frelinger JA, Galgiani JN.

Vaccine. 2018 May 31;36(23):3375-3380. doi: 10.1016/j.vaccine.2018.04.026. Epub 2018 Apr 30.

7.

Top Questions in the Diagnosis and Treatment of Coccidioidomycosis.

Donovan FM, Zangeneh TT, Malo J, Galgiani JN.

Open Forum Infect Dis. 2017 Sep 12;4(4):ofx197. doi: 10.1093/ofid/ofx197. eCollection 2017 Fall.

8.

Oxygen Consumption Deficits in Patients With Residual Fatigue After Primary Coccidioidomycosis.

Ganley KJ, Bosch PR, Blair JE, Rischard F, Galgiani JN.

Open Forum Infect Dis. 2017 Jun 26;4(3):ofx136. doi: 10.1093/ofid/ofx136. eCollection 2017 Summer.

9.

Risk Factors for Disseminated Coccidioidomycosis, United States.

Odio CD, Marciano BE, Galgiani JN, Holland SM.

Emerg Infect Dis. 2017 Feb;23(2). doi: 10.3201/eid2302.160505.

10.

Effect of Geography on the Analysis of Coccidioidomycosis-Associated Deaths, United States.

Noble JA, Nelson RG, Fufaa GD, Kang P, Shafir SC, Galgiani JN.

Emerg Infect Dis. 2016 Oct;22(10):1821-3. doi: 10.3201/eid2210.160696.

11.

Executive Summary: 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.

Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, Johnson RH, Kusne S, Lisse J, MacDonald JD, Meyerson SL, Raksin PB, Siever J, Stevens DA, Sunenshine R, Theodore N.

Clin Infect Dis. 2016 Sep 15;63(6):717-22. doi: 10.1093/cid/ciw538.

PMID:
27559032
12.

A Coccidioides posadasii CPS1 Deletion Mutant Is Avirulent and Protects Mice from Lethal Infection.

Narra HP, Shubitz LF, Mandel MA, Trinh HT, Griffin K, Buntzman AS, Frelinger JA, Galgiani JN, Orbach MJ.

Infect Immun. 2016 Sep 19;84(10):3007-16. doi: 10.1128/IAI.00633-16. Print 2016 Oct.

13.

2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.

Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, Johnson RH, Kusne S, Lisse J, MacDonald JD, Meyerson SL, Raksin PB, Siever J, Stevens DA, Sunenshine R, Theodore N.

Clin Infect Dis. 2016 Sep 15;63(6):e112-46. doi: 10.1093/cid/ciw360. Epub 2016 Jul 27.

PMID:
27470238
14.

Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models.

Shubitz LF, Trinh HT, Galgiani JN, Lewis ML, Fothergill AW, Wiederhold NP, Barker BM, Lewis ER, Doyle AL, Hoekstra WJ, Schotzinger RJ, Garvey EP.

Antimicrob Agents Chemother. 2015 Dec;59(12):7249-54. doi: 10.1128/AAC.00593-15. Epub 2015 Sep 14.

15.

A paradigm for the evaluation and management of spinal coccidioidomycosis.

Martirosyan NL, Skoch JM, Zaninovich O, Zoccali C, Galgiani JN, Baaj AA.

Surg Neurol Int. 2015 Jun 17;6:107. doi: 10.4103/2152-7806.158979. eCollection 2015. Review.

16.

The Return of Delayed-Type Hypersensitivity Skin Testing for Coccidioidomycosis.

Wack EE, Ampel NM, Sunenshine RH, Galgiani JN.

Clin Infect Dis. 2015 Sep 1;61(5):787-91. doi: 10.1093/cid/civ388. Epub 2015 May 15. Review.

PMID:
25979308
17.

Application of immunosignatures for diagnosis of valley fever.

Navalkar KA, Johnston SA, Woodbury N, Galgiani JN, Magee DM, Chicacz Z, Stafford P.

Clin Vaccine Immunol. 2014 Aug;21(8):1169-77. doi: 10.1128/CVI.00228-14. Epub 2014 Jun 25.

18.

Modeling nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials.

Shubitz LF, Trinh HT, Perrill RH, Thompson CM, Hanan NJ, Galgiani JN, Nix DE.

J Infect Dis. 2014 Jun 15;209(12):1949-54. doi: 10.1093/infdis/jiu029. Epub 2014 Jan 12.

19.

Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis.

Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, Orbach MJ, Galgiani JN.

Clin Microbiol Rev. 2013 Jul;26(3):505-25. doi: 10.1128/CMR.00005-13. Review.

20.

Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis.

Sampaio EP, Hsu AP, Pechacek J, Bax HI, Dias DL, Paulson ML, Chandrasekaran P, Rosen LB, Carvalho DS, Ding L, Vinh DC, Browne SK, Datta S, Milner JD, Kuhns DB, Long Priel DA, Sadat MA, Shiloh M, De Marco B, Alvares M, Gillman JW, Ramarathnam V, de la Morena M, Bezrodnik L, Moreira I, Uzel G, Johnson D, Spalding C, Zerbe CS, Wiley H, Greenberg DE, Hoover SE, Rosenzweig SD, Galgiani JN, Holland SM.

J Allergy Clin Immunol. 2013 Jun;131(6):1624-34. doi: 10.1016/j.jaci.2013.01.052. Epub 2013 Mar 28.

21.

Efficacy of Nikkomycin Z for respiratory coccidioidomycosis in naturally infected dogs.

Shubitz LF, Roy ME, Nix DE, Galgiani JN.

Med Mycol. 2013 Oct;51(7):747-54. doi: 10.3109/13693786.2013.770610. Epub 2013 Mar 14.

PMID:
23488972
22.

Elements of style in managing coccidioidomycosis.

Galgiani JN.

Clin Infect Dis. 2013 Jun;56(11):1586-8. doi: 10.1093/cid/cit117. Epub 2013 Mar 5. No abstract available.

PMID:
23463638
23.

Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs.

Taroumian S, Knowles SL, Lisse JR, Yanes J, Ampel NM, Vaz A, Galgiani JN, Hoover SE.

Arthritis Care Res (Hoboken). 2012 Dec;64(12):1903-9. doi: 10.1002/acr.21784.

24.

Mouse models for the study of fungal pneumonia: a collection of detailed experimental protocols for the study of Coccidioides, Cryptococcus, Fusarium, Histoplasma and combined infection due to Aspergillus-Rhizopus.

Muhammed M, Feldmesser M, Shubitz LF, Lionakis MS, Sil A, Wang Y, Glavis-Bloom J, Lewis RE, Galgiani JN, Casadevall A, Kontoyiannis DP, Mylonakis E.

Virulence. 2012 May 1;3(3):329-38. doi: 10.4161/viru.20142. Epub 2012 May 1.

25.

The public health impact of coccidioidomycosis in Arizona and California.

Hector RF, Rutherford GW, Tsang CA, Erhart LM, McCotter O, Anderson SM, Komatsu K, Tabnak F, Vugia DJ, Yang Y, Galgiani JN.

Int J Environ Res Public Health. 2011 Apr;8(4):1150-73. doi: 10.3390/ijerph8041150. Epub 2011 Apr 15. Review.

26.

Interleukin-12 receptor β1 deficiency predisposing to disseminated Coccidioidomycosis.

Vinh DC, Schwartz B, Hsu AP, Miranda DJ, Valdez PA, Fink D, Lau KP, Long-Priel D, Kuhns DB, Uzel G, Pittaluga S, Hoover S, Galgiani JN, Holland SM.

Clin Infect Dis. 2011 Feb 15;52(4):e99-e102. doi: 10.1093/cid/ciq215. No abstract available.

27.

T-lymphocyte predominance in lesions of canine coccidioidomycosis.

Shubitz LF, Dial SM, Galgiani JN.

Vet Pathol. 2011 Sep;48(5):1008-11. doi: 10.1177/0300985810384410. Epub 2010 Oct 7.

PMID:
20930107
28.

An insight into the antifungal pipeline: selected new molecules and beyond.

Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH.

Nat Rev Drug Discov. 2010 Sep;9(9):719-27. doi: 10.1038/nrd3074. Epub 2010 Aug 20. Review.

PMID:
20725094
29.

Population genomic sequencing of Coccidioides fungi reveals recent hybridization and transposon control.

Neafsey DE, Barker BM, Sharpton TJ, Stajich JE, Park DJ, Whiston E, Hung CY, McMahan C, White J, Sykes S, Heiman D, Young S, Zeng Q, Abouelleil A, Aftuck L, Bessette D, Brown A, FitzGerald M, Lui A, Macdonald JP, Priest M, Orbach MJ, Galgiani JN, Kirkland TN, Cole GT, Birren BW, Henn MR, Taylor JW, Rounsley SD.

Genome Res. 2010 Jul;20(7):938-46. doi: 10.1101/gr.103911.109. Epub 2010 Jun 1.

30.

Coccidioidomycosis among scholarship athletes and other college students, Arizona, USA.

Stern NG, Galgiani JN.

Emerg Infect Dis. 2010 Feb;16(2):321-3. doi: 10.3201/eid1602.090918.

31.

Comparative genomic analyses of the human fungal pathogens Coccidioides and their relatives.

Sharpton TJ, Stajich JE, Rounsley SD, Gardner MJ, Wortman JR, Jordar VS, Maiti R, Kodira CD, Neafsey DE, Zeng Q, Hung CY, McMahan C, Muszewska A, Grynberg M, Mandel MA, Kellner EM, Barker BM, Galgiani JN, Orbach MJ, Kirkland TN, Cole GT, Henn MR, Birren BW, Taylor JW.

Genome Res. 2009 Oct;19(10):1722-31. doi: 10.1101/gr.087551.108. Epub 2009 Aug 28.

32.

Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency.

Vinh DC, Masannat F, Dzioba RB, Galgiani JN, Holland SM.

Clin Infect Dis. 2009 Sep 15;49(6):e62-5. doi: 10.1086/605532.

33.

Pharmacokinetics of nikkomycin Z after single rising oral doses.

Nix DE, Swezey RR, Hector R, Galgiani JN.

Antimicrob Agents Chemother. 2009 Jun;53(6):2517-21. doi: 10.1128/AAC.01609-08. Epub 2009 Apr 6.

34.

Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis.

Ampel NM, Giblin A, Mourani JP, Galgiani JN.

Clin Infect Dis. 2009 Jan 15;48(2):172-8. doi: 10.1086/595687.

PMID:
19072555
35.

Vaccine-induced cellular immune responses differ from innate responses in susceptible and resistant strains of mice infected with Coccidioides posadasii.

Shubitz LF, Dial SM, Perrill R, Casement R, Galgiani JN.

Infect Immun. 2008 Dec;76(12):5553-64. doi: 10.1128/IAI.00885-08. Epub 2008 Oct 13.

36.

Vaccines to prevent systemic mycoses: holy grails meet translational realities.

Galgiani JN.

J Infect Dis. 2008 Apr 1;197(7):938-40. doi: 10.1086/529205. No abstract available.

37.

Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis.

Catanzaro A, Cloud GA, Stevens DA, Levine BE, Williams PL, Johnson RH, Rendon A, Mirels LF, Lutz JE, Holloway M, Galgiani JN.

Clin Infect Dis. 2007 Sep 1;45(5):562-8. Epub 2007 Jul 23.

PMID:
17682989
38.

Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis).

Johnson SM, Lerche NW, Pappagianis D, Yee JL, Galgiani JN, Hector RF.

Ann N Y Acad Sci. 2007 Sep;1111:290-300. Epub 2007 Mar 8.

PMID:
17347333
39.

The application of proteomic techniques to fungal protein identification and quantification.

Rohrbough JG, Galgiani JN, Wysocki VH.

Ann N Y Acad Sci. 2007 Sep;1111:133-46. Epub 2007 Mar 7. Review.

PMID:
17344531
40.

Coccidioidomycosis: changing perceptions and creating opportunities for its control.

Galgiani JN.

Ann N Y Acad Sci. 2007 Sep;1111:1-18. Epub 2007 Mar 7. Review.

PMID:
17344530
41.

Nuclear labeling of Coccidioides posadasii with green fluorescent protein.

Li L, Schmelz M, Kellner EM, Galgiani JN, Orbach MJ.

Ann N Y Acad Sci. 2007 Sep;1111:198-207. Epub 2007 Mar 7.

PMID:
17344520
42.

Efficacy of ambruticin analogs in a murine model of coccidioidomycosis.

Shubitz LF, Galgiani JN, Tian ZQ, Zhong Z, Timmermans P, Katz L.

Antimicrob Agents Chemother. 2006 Oct;50(10):3467-9.

43.

Coccidioides posadasii contains single chitin synthase genes corresponding to classes I to VII.

Mandel MA, Galgiani JN, Kroken S, Orbach MJ.

Fungal Genet Biol. 2006 Nov;43(11):775-88. Epub 2006 Jul 20.

PMID:
16857399
44.

Improved protection of mice against lethal respiratory infection with Coccidioides posadasii using two recombinant antigens expressed as a single protein.

Shubitz LF, Yu JJ, Hung CY, Kirkland TN, Peng T, Perrill R, Simons J, Xue J, Herr RA, Cole GT, Galgiani JN.

Vaccine. 2006 Jul 26;24(31-32):5904-11. Epub 2006 Apr 18.

PMID:
16759762
45.

Coccidioidomycosis as a common cause of community-acquired pneumonia.

Valdivia L, Nix D, Wright M, Lindberg E, Fagan T, Lieberman D, Stoffer T, Ampel NM, Galgiani JN.

Emerg Infect Dis. 2006 Jun;12(6):958-62. Erratum in: Emerg Infect Dis. 2006 Aug;12(8):1307.

46.

Spherules derived from Coccidioides posadasii promote human dendritic cell maturation and activation.

Dionne SO, Podany AB, Ruiz YW, Ampel NM, Galgiani JN, Lake DF.

Infect Immun. 2006 Apr;74(4):2415-22.

48.

Coccidioidomycosis.

Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, Williams PL; Infectious Diseases Society of America.

Clin Infect Dis. 2005 Nov 1;41(9):1217-23. Epub 2005 Sep 20. Review. No abstract available.

PMID:
16206093
49.

An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001.

Park BJ, Sigel K, Vaz V, Komatsu K, McRill C, Phelan M, Colman T, Comrie AC, Warnock DW, Galgiani JN, Hajjeh RA.

J Infect Dis. 2005 Jun 1;191(11):1981-7. Epub 2005 Apr 20.

PMID:
15871133
50.

Coccidioides posadasii contains a single 1,3-beta-glucan synthase gene that appears to be essential for growth.

Kellner EM, Orsborn KI, Siegel EM, Mandel MA, Orbach MJ, Galgiani JN.

Eukaryot Cell. 2005 Jan;4(1):111-20.

Supplemental Content

Loading ...
Support Center